# A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

> **NCT02009631** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 45 (actual)

## Conditions studied

- Breast Cancer
- Ovarian Cancer
- Colon Cancer
- Lung Cancer
- Gastric Cancer
- Solid Tumors

## Interventions

- **DRUG:** Veliparib (ABT-888)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02009631
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02009631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02009631, "A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02009631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*